Analyst Price Target Update on Bruker Corporation (NASDAQ:BRKR)

Bruker Corporation (NASDAQ:BRKR): The stock price is expected to reach $ 29 in the short term. The number of analysts agreeing with this consensus is 10. The higher estimate for the short term price target is at $34 while the lower estimate is at $25. The standard deviation of the price stands at $2.91.

Many analysts have stated their opinion on the company shares. Equity analysts at the Brokerage firm BTIG Research downgrades its rating on Bruker Corporation (NASDAQ:BRKR). The rating major has initiated the coverage with neutral rating on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on May 5, 2016. Company shares have received an average consensus rating of Hold for the current week

On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director 10% owner of Bruker Corp, Laukien Joerg C had sold 2,000,000 shares worth of $51,300,000 in a transaction dated June 6, 2016. In this transaction, 2,000,000 shares were sold at $25.65 per share.

Bruker Corporation (NASDAQ:BRKR) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.45 points or 1.81% at $24.35 with 1,383,590 shares getting traded. Post opening the session at $24.84, the shares hit an intraday low of $24.32 and an intraday high of $24.89 and the price was in this range throughout the day. The company has a market cap of $3,931 million and the number of outstanding shares have been calculated to be 161,454,760 shares. The 52-week high of Bruker Corporation (NASDAQ:BRKR) is $29.85 and the 52-week low is $15.778.

Bruker Corporation is a designer and manufacturer of life science and materials research systems and associated products that address the needs of a range of customers in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology and in-vitro diagnostics. The Company operates through two segments: Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST). BSI is organized into three operating segments: the Bruker BioSpin Group, the Bruker CALID Group and the Bruker Nano Group. BEST designs, manufactures and distributes superconducting materials. The company maintains technical and manufacturing centers in Europe and North America, and it has sales offices located throughout the world.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.